Buscar en
Enfermedades Infecciosas y Microbiología Clínica (English Edition)
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica (English Edition) Hemolytic anemia in pediatric patients treated with artesunate for severe malari...
Journal Information
Vol. 38. Issue 3.
Pages 139-140 (March 2020)
Vol. 38. Issue 3.
Pages 139-140 (March 2020)
Letter to the Editor
DOI: 10.1016/j.eimce.2019.06.008
Full text access
Hemolytic anemia in pediatric patients treated with artesunate for severe malaria
Anemia hemolítica tardía en niños tratados con artesunato intravenoso por malaria grave
Lidia Rabaneda-Gutiérreza,
Corresponding author
, Pedro Jesús Alcalá-Minagorrea, Antonia Sánchez-Bautistab
a Servicio de Pediatría, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, Spain
b Sección de Microbiología, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, Spain
Article information
Full Text
Download PDF
Full Text
Dear Editor:

Intravenous artesunate is currently the recommended first-line treatment in cases of severe malaria, with a reduction in death rates of 23% in children compared with quinine. Although it demonstrates an acceptable safety profile compared with other drugs, the potential for haemolytic anaemia associated with its use has been described.1–3

Three cases of paediatric patients treated with artemisinin derivatives for severe imported malaria who subsequently developed haemolytic anaemia have been described. The three patients were born in Spain, with no personal history of previous malaria.

Two sisters aged 6 and 4 years old were diagnosed with severe Plasmodium falciparum (P. falciparum) malaria at our centre, with parasitaemia of 5% and 15% respectively. There was history of a recent stay in Senegal without antimalarial prophylaxis. They received treatment with intravenous artesunate (2.4 mg/kg/dose, every 12 h for the first two doses, and subsequently every 24 h), with a cumulative number of 5 doses for the older sister and 4 doses for the younger, followed by piperaquine-artenimol for 3 days. Both were afebrile with disappearance of the parasitaemia during the first 48 h. In laboratory test follow-up, parameters compatible with haemolytic anaemia were observed at 10 days after start of treatment: drop in haemoglobin to 7.4 mg/dl (in the follow-up 5 days before, haemoglobin was 9 g/dL) in the older sister and 6.3 mg/dl (in the follow-up 5 days before, haemoglobin was 8.8 g/dL) in the younger, increase in LDH to 751 U/L (previous follow-up 674 U/L) and 1831 U/L (previous follow-up 738 U/L) respectively, undetectable haptoglobin levels and negative Coombs test in both cases. In the face of suspected haemolytic anaemia secondary to artemisinins, and once haemoglobinopathies had been ruled out, treatment was started with prednisolone at 1 mg/kg/day for 3 days with good clinical and lab test evolution although one of the patients, the older sister, required a packed red blood cell transfusion due to haemoglobin of 6.3 g/dL.

A 6-year-old boy is transferred to our site with a diagnosis of malaria due to P. falciparum and Plasmodium vivax in light of the need for intensive care (parasitaemia 25%). There was history of a recent extended stay in Gambia, without antimalarial prophylaxis. At his site of origin he was treated with proguanil/atovaquone, with a poor clinical and lab test response at 24 h after admission. In ICU he was treated with cefotaxime and intravenous artesunate (2.4 mg/kg dose, 0.12 and 24 h) followed by piperaquine-artenimol 3 days with a favourable response. At 8 days of evolution haemolysis findings were detected: haemoglobin of 7.5 g/dL (drop of 2 g/dL compared to previous follow-up, 9.9 g/dL) was detected, hyperbilirubinaemia of 2.08 mg/dL (previous follow-up 1.5 mg/dL), elevation of LDH to 1831 IU/L (previous follow-up 354 IU/L), undetectable levels of haptoglobin and positive Coombs test), haemoglobinopathies test within normal range. In the face of suspected haemolytic anaemia secondary to artemisinins, prednisolone was started at 1 mg/kg/day for 3 days with favourable clinical and lab test evolution.

Artemisinin derivatives have become the first-line option for the treatment of severe malaria. Their most common side effects are mild, although haemolytic anaemia secondary to their use has also been described, with an estimated incidence of between 7–21% of cases treated with an intravenous artesunate, especially in patients with a higher degree of parasitaemia,4 although cases of haemolysis associated with treatment with oral artemisinins have also been described.5 It usually appears between the first and fourth weeks after the start of its administration, and it is a different process from blackwater fever associated with treatment with quinine, which usually appears earlier.6 The ultimate cause of haemolysis is unknown, although several hypotheses have been put forward. One of these is the removal at the splenic level of the previously infected red blood cells, with inclusion bodies, due to the phenomenon of «pitting».7,8 An immune mechanism has also been put forward, since in some patients a positive Coombs test has been observed,9 such as the third case presented, and a favourable response to corticosteroids, although the role of this therapy has not been clearly established.10 Other approaches have also been posed, such as direct toxicity of an artesunate metabolite, dihydroartemisinin. There are also factors that favour a greater individual predisposition, such as haemoglobinopathies (sickle cell disease or glucose-6-phosphate dehydrogenase deficiency) or due to interindividual variability in drug metabolic pathways.

Haemolytic anaemia is a potential complication associated with treatment with intravenous artesunate in paediatric patients, for which reason its appearance must be monitored for during the weeks following its administration, especially in patients with high parasitaemias.

J. Muñoz, G. Rojo-Marcos, G. Ramírez-Olivencia, J. Salas-Coronas, B. Treviño, J.L. Perez, et al.
Diagnóstico y tratamiento de la malaria importada en España: recomendaciones del Grupo de Trabajo de Malaria de la Sociedad Española de Medicina Tropical y Salud Internacional (SEMTSI).
Enferm Infecc Microbiol Clin, 33 (2015), pp. 1-13
C. Fanello, M. Onyamboko, S.J. Lee, C. Woodrow, S. Setaphan, K. Chotivanich, A.M. Dondorp.
Post-treatment haemolysis in African children with hyperpara- sitaemic falciparum malaria; a randomized comparison of artesunate and quinine.
BMC Infect Dis, 17 (2017), pp. 575
F. Kurth, M. Develoux, M. Mechain, D. Malvy, J. Clerinx, S. Antinori, et al.
Severe malaria in Europe: an 8-year multi-centre observational study.
L. Raffray, M.C. Receveur, M. Beguet, P. Lauroua, T. Pistone, D. Malvy.
Severe de- layed autoimmune haemolytic anaemia following artesunate administration in severe malaria: a case report.
F. Kurth, T. Lingscheid, F. Steiner, M.S. Stegemann, S. Bélard, N. Menner, et al.
Hemolysis after Oral Artemisinin Combination Therapy for Uncomplicated Plasmosium falciparum Malaria.
Emerg Infect Dis, 22 (2016), pp. 1381-1386
N. Domínguez-Pinilla, M.R. Del Fresno-Valencia, V. Pérez-Alonso, L.I. González- Granado.
Anemia hemolítica tardía secundaria al tratamiento con artesunato por vía intravenosa.
An Pediatr (Barc), 82 (2015), pp. e240-1
T. Aldámiz-Echevarría Lois, A. López-Polín, F.F. Norman, B. Monge-Maillo, R. López-Vélez, J.A. Perez-Molina.
Delayed haemolysis secondary to treatment of severe malaria with intravenous artesunate: Report on the experience of a referral centre for tropical infec- tions in Spain.
Travel Med Infect Dis, 15 (2017), pp. 52-56
T. Rolling, T. Agbenyega, S. Issifou, A.A. Adegnika, J. Sylverken, D. Spahlinger, et al.
Delayed hemolysis after treatment with parenteral artesunate in African children with severe malaria – A double-center prospective study.
J Infect Dis, 209 (2014), pp. 1921-1928
D. Camprubí, A. Pereira, N. Rodríguez-Valero, A. Almuedo, R. Varo, C. Casals-Pascual, et al.
Positive direct antiglobulin test in postartesunate delayed haemolysis: more tan a coincidence?.
D. Lebrun, T. Floch, A. Brunet, G. Julien, J. Romaru, Y. N’Guyen, et al.
Severe post- artesunate delayed onset anaemia responding to corticotherapy: a case report.
J Travel Med, 25 (2018),

Please cite this article as: Rabaneda-Gutiérrez L, Alcalá-Minagorre PJ, Sánchez-Bautista A. Anemia hemolítica tardía en niños tratados con artesunato intravenoso por malaria grave. Enferm Infecc Microbiol Clin. 2020;38:139–140.

Copyright © 2019. Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos